STOCK TITAN

Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, announced its participation in the 36th Annual Piper Sandler Healthcare Conference in New York. The company's Founder & CEO Sean McClain will join a panel discussion on 'The Promise of AI in Drug Development' scheduled for Thursday, December 5th at 2:00 p.m. Eastern Time. Those interested in attending can request registration details through their Piper Sandler representative.

Absci (Nasdaq: ABSI), un'azienda di creazione di farmaci generativa basata sui dati, ha annunciato la sua partecipazione alla 36ª Conferenza annuale di Piper Sandler sulla sanità a New York. Il Fondatore e CEO dell'azienda, Sean McClain, parteciperà a un panel di discussione su 'La promessa dell'IA nello sviluppo di farmaci', programmata per giovedì 5 dicembre alle 14:00 ora orientale. Gli interessati a partecipare possono richiedere dettagli sull'iscrizione tramite il proprio rappresentante di Piper Sandler.

Absci (Nasdaq: ABSI), una empresa de creación de fármacos generativa basada en datos, anunció su participación en la 36ª Conferencia Anual de Atención Médica de Piper Sandler en Nueva York. El Fundador y CEO de la empresa, Sean McClain, participará en un panel de discusión sobre 'La Promesa de la IA en el Desarrollo de Fármacos', programado para el jueves 5 de diciembre a las 2:00 p.m. hora del Este. Aquellos interesados en asistir pueden solicitar detalles de inscripción a través de su representante de Piper Sandler.

Absci (Nasdaq: ABSI), 데이터 우선 생성 AI 약물 개발 회사, 뉴욕에서 열리는 제36회 파이퍼 샌들러 헬스케어 컨퍼런스에 참석한다고 발표했습니다. 회사의 설립자이자 CEO인 Sean McClain은 12월 5일 목요일 오후 2시(동부 표준시)에 예정된 '약물 개발에서 AI의 가능성'에 관한 패널 토론에 참석할 예정입니다. 참석을 원하는 분들은 파이퍼 샌들러 대표를 통해 등록 세부정보를 요청할 수 있습니다.

Absci (Nasdaq: ABSI), une entreprise de création de médicaments générative axée sur les données, a annoncé sa participation à la 36e Conférence Annuelle de Santé de Piper Sandler à New York. Le Fondateur et PDG de l'entreprise, Sean McClain, participera à une discussion en panel intitulée 'La Promesse de l'IA dans le Développement de Médicaments', prévue pour le jeudi 5 décembre à 14h00, heure de l'Est. Les personnes intéressées à assister peuvent demander des détails d'inscription par l'intermédiaire de leur représentant Piper Sandler.

Absci (Nasdaq: ABSI), ein datengestütztes Unternehmen für generative KI in der Arzneimittelentwicklung, gab seine Teilnahme an der 36. jährlichen Piper Sandler Healthcare-Konferenz in New York bekannt. Der Gründer und CEO des Unternehmens, Sean McClain, wird an einer Podiumsdiskussion über 'Das Versprechen von KI in der Arzneimittelentwicklung' teilnehmen, die für Donnerstag, den 5. Dezember um 14:00 Uhr Eastern Time angesetzt ist. Interessierte, die teilnehmen möchten, können über ihren Piper Sandler-Vertreter um Registrierungsdetails bitten.

Positive
  • None.
Negative
  • None.

VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 36th Annual Piper Sandler Healthcare Conference in New York, NY.

Absci’s Founder & CEO Sean McClain is scheduled to participate in a panel discussion titled “The Promise of AI in Drug Development” on Thursday, December 5th at 2:00 p.m. Eastern Time.

Interested parties may contact their Piper Sandler representative to request registration details for this live event.

About Absci

Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.

Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com

Media Contact
press@absci.com


FAQ

When is Absci (ABSI) participating in the Piper Sandler Healthcare Conference 2024?

Absci (ABSI) is participating on Thursday, December 5th, 2024, at 2:00 p.m. Eastern Time.

What panel is Absci (ABSI) participating in at the Piper Sandler Healthcare Conference?

Absci's CEO Sean McClain is participating in a panel discussion titled 'The Promise of AI in Drug Development.'

How can investors attend Absci's (ABSI) panel at the Piper Sandler Conference?

Interested parties need to contact their Piper Sandler representative to request registration details for the live event.

Where is the 36th Annual Piper Sandler Healthcare Conference with Absci (ABSI) being held?

The conference is being held in New York, NY.

Absci Corporation

NASDAQ:ABSI

ABSI Rankings

ABSI Latest News

ABSI Stock Data

333.66M
90.93M
20.09%
62.57%
10.45%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States of America
VANCOUVER